<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Victoria Hendrick, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Keck, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1564395">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among women with an established pregnancy, surveys estimate that psychotropic drugs are taken by 21 to 33 percent [
         <a href="#rid1">
          1,2
         </a>
         ]. Although these medications are often necessary to control a psychiatric illness that predates or emerges during pregnancy, pharmacotherapy entails risks of structural malformations, pregnancy complications, neonatal toxicity and withdrawal, and adverse developmental effects.
        </p>
        <p>
         This topic reviews the risks of antipsychotics, benzodiazepines,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and electroconvulsive therapy during pregnancy. The risks of antidepressants and antiepileptics during pregnancy and the principles of teratology are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/89067.html" rel="external">
          "Antenatal use of antidepressants and the potential risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">
          "Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Effects of ASMs on the fetus and child'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2940.html" rel="external">
          "Congenital anomalies: Approach to evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1564402">
         <span class="h1">
          DEFINITION OF A TERATOGEN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Teratogens are factors that can alter normal intrauterine development of fetal growth, anatomic structures, physical functioning, and postnatal development. This definition encompasses environmental exposures, maternal medical disorders, infectious agents, and genetic conditions.
        </p>
        <p>
         Most discussions of teratogens usually center on drug exposures. In determining whether a drug is a teratogen, many authorities stipulate that the exposure causes a pattern of defects [
         <a href="#rid3">
          3
         </a>
         ]. Thus, if exposure is associated with an increase in birth defects greater than that expected in the general population, but the defects vary and there is no discernible pattern, the drug is generally not considered teratogenic. An overview of teratology is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/110900.html" rel="external">
          "Congenital anomalies: Causes", section on 'Teratogens'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1564426">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         All psychotropic drugs presumably cross the placenta and are present in the amniotic fluid [
         <a href="#rid4">
          4
         </a>
         ]. Embryonic and fetal exposure to maternal pharmacotherapy can cause [
         <a href="#rid2">
          2,5-7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Miscarriage
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Major and minor structural malformations
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal growth restriction and low birth weight
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preterm delivery
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neonatal toxicity and withdrawal
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postnatal developmental effects upon behavior, cognition, and emotional regulation
        </p>
        <p>
        </p>
        <p>
         Medication effects upon the fetus vary according to gestational age [
         <a href="#rid2">
          2,5,7
         </a>
         ]. As an example, the fetus is most vulnerable to major morphologic teratogenesis during organogenesis in the embryonic period of the first trimester, between the third and eighth week of gestation (weeks of gestation are counted from the first day of the last menstrual period)  (
         <a class="graphic graphic_figure graphicRef65816" href="/z/d/graphic/65816.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef56642" href="/z/d/graphic/56642.html" rel="external">
          figure 2
         </a>
         ). Organogenesis occurs 5 to 10 weeks from the first day of the last menstrual period, or 3 to 8 weeks from conception (conception occurs approximately two weeks after the first day of the last menstrual period). By contrast, neonatal toxicity and withdrawal are the result of third trimester exposure.
        </p>
        <p>
         The estimated risk of major congenital malformations appears to vary among psychotropic medications; the rank order from greatest to least teratogenic risk is [
         <a href="#rid8">
          8-13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          Valproate
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          Carbamazepine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          Lamotrigine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antipsychotics
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antidepressants
        </p>
        <p>
        </p>
        <p>
         In discussing teratogenic effects, patients should be informed that the base rate for congenital defects in the general population is at least two to five percent [
         <a href="#rid14">
          14-17
         </a>
         ]. The incidence of defects is two to three percent at birth but increases to five percent or higher after one year when hidden defects are discovered.
        </p>
        <p>
         The estimated risks of congenital defects from pharmacotherapy are typically based upon birth registry and observational studies [
         <a href="#rid6">
          6
         </a>
         ]. Although these studies probably provide the best evidence of the risks, the accuracy of these estimates is uncertain due to ascertainment bias. In addition, information about teratogenic effects is usually presented in terms of monotherapy, whereas many studies are confounded due to concomitant exposure to multiple psychotropic and nonpsychotropic medications [
         <a href="#rid18">
          18
         </a>
         ], and acutely ill pregnant patients often require medication combinations [
         <a href="#rid19">
          19-22
         </a>
         ]. Further, it is often not possible to separate the effects of drugs from the psychiatric illness itself, and studies often do not control for potential confounding factors, such as comorbid substance use disorder, maternal age, maternal body mass index, and prior miscarriages.
        </p>
        <p>
         Although a drug may increase the risk of a congenital anomaly, the absolute risk may be low [
         <a href="#rid23">
          23
         </a>
         ]. As an example, the estimated risk of Ebstein anomaly (abnormalities of the tricuspid valve and right ventricle) in the general population is 1 in 20,000 live births [
         <a href="#rid24">
          24-26
         </a>
         ]. Following first-trimester exposure to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , the risk increases 20-fold to approximately 1 in 1000, which many authorities consider low [
         <a href="#rid5">
          5,23,27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1561478">
         <span class="h2">
          Resources
         </span>
         <span class="headingEndMark">
          —
         </span>
         Current information about the possible teratogenic effects of medications is available from several resources; these are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2940.html" rel="external">
          "Congenital anomalies: Approach to evaluation"
         </a>
         .)
        </p>
        <p>
         In addition, the possible teratogenic effects of drugs and suggestions for managing them can be found for all drugs included in the UpToDate drug database: search on the drug name, choose the drug information topic for that drug, and click on the “Pregnancy Implications” section of the topic outline. Clicking on the name of a drug cited within any UpToDate topic will also bring you to the drug information topic.
        </p>
        <p class="headingAnchor" id="H189791683">
         <span class="h1">
          QUALITY OF EVIDENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The quality of evidence that informs us about the risks of psychotropic drugs during pregnancy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/89067.html" rel="external">
          "Antenatal use of antidepressants and the potential risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors", section on 'Quality of evidence'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1564785">
         <span class="h1">
          ANTIPARKINSONIAN DRUGS USED FOR TREATING EXTRAPYRAMIDAL SYMPTOMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among the antiparkinsonian drugs that are used to treat extrapyramidal symptoms secondary to antipsychotics, reviews suggest that the risk of teratogenicity with antihistamines (eg,
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         ) appears to be low [
         <a href="#rid28">
          28
         </a>
         ], and that organ malformation appears to be less likely with diphenhydramine than
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">
          benztropine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         [
         <a href="#rid23">
          23,29
         </a>
         ]. As an example, a study used an administrative claims database to identify 270 infants exposed to diphenhydramine during the first trimester and found no association with congenital defects [
         <a href="#rid30">
          30
         </a>
         ]. However, other studies have found that prenatal use of diphenhydramine was associated with congenital malformations [
         <a href="#rid4">
          4
         </a>
         ], including a case-control study in which prenatal exposure to diphenhydramine was greater among children with oral clefts (n = 599) than controls (n = 500) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1561485">
         <span class="h1">
          ANTIDEPRESSANTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Much of the evidence about the teratogenicity, pregnancy complications, and postnatal risks associated with antidepressants is based upon observational studies of pregnant patients with unipolar major depression.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/89067.html" rel="external">
          "Antenatal use of antidepressants and the potential risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/100334.html" rel="external">
          "Antenatal use of antidepressants and risks of teratogenicity and adverse pregnancy outcomes: Drugs other than selective serotonin reuptake inhibitors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5007.html" rel="external">
          "Antenatal exposure to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs): Neonatal outcomes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1561492">
         <span class="h1">
          ANTIEPILEPTICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most observational studies that have examined the association between antiepileptics and congenital malformations and postnatal risks have been conducted primarily in pregnant patients with epilepsy. (See
         <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">
          "Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Effects of ASMs on the fetus and child'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1561506">
         <span class="h1">
          ANTIPSYCHOTICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         First-generation antipsychotics have often been used and studied during pregnancy [
         <a href="#rid2">
          2,32
         </a>
         ]. However, the risks of prenatal exposure to first-generation antipsychotics have been examined primarily in patients with hyperemesis gravidarum who received low doses of antipsychotics as antiemetics and were presumed to not have a psychiatric disorder, and secondarily in patients with psychotic disorders and mood disorders [
         <a href="#rid23">
          23,32
         </a>
         ].
        </p>
        <p>
         Second-generation antipsychotics are more widely used during pregnancy than first-generation drugs. A study of administrative claims data (n &gt;580,000 pregnant women) found that antenatal exposure to second-generation antipsychotics (primarily
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ) occurred in 0.7 percent of the women, whereas first-generation antipsychotic (most commonly
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         ) exposure occurred in 0.1 percent [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10923777">
         <span class="h2">
          Maternal weight gain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postpartum maternal weight may be greater than prepregnancy weight due to the use of antipsychotics during pregnancy. A national birth registry of pregnancies (n &gt;900,000) found that a body mass index ≥26 (overweight or obesity) following delivery was more probable in patients treated with antipsychotics than untreated women (odds ratio 2) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10923752">
         <span class="h2">
          Placental passage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fetal exposure to antipsychotics may vary due to differences in placental permeability to these drugs. A prospective observational study of 50 pregnant patients examined the placental passage of antipsychotics, defined as the ratio of umbilical cord serum drug concentration to maternal serum drug concentration [
         <a href="#rid21">
          21
         </a>
         ]. (Umbilical cord and maternal plasma concentrations were drawn at delivery; drugs cross the placenta more readily late in pregnancy.) The placental passage ratios were as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          Olanzapine
         </a>
         – 72 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          Haloperidol
         </a>
         – 66
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          Risperidone
         </a>
         – 49
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          Quetiapine
         </a>
         – 24
        </p>
        <p>
        </p>
        <p>
         The ratio for
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         was lower than that for
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         and
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         .
        </p>
        <p class="headingAnchor" id="H1570026">
         <span class="h2">
          Teratogenicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most studies have generally found that prenatal exposure to first- and second-generation antipsychotics did not increase the risk of major physical malformations above rates observed in the general population [
         <a href="#rid3">
          3,32,34,35
         </a>
         ]. As an example, one study examined live births (n &gt;1,300,000) that included infants with first trimester exposure to first- and second-generation antipsychotics (n &gt;9000) [
         <a href="#rid36">
          36
         </a>
         ]. After adjusting for potential confounding factors (eg, maternal age, indications for antipsychotics, and concomitant medications), the analyses found that rates of congenital and cardiovascular defects were comparable in the exposed and unexposed children, with the exception of
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , which was associated with a small increased risk in overall malformations (risk ratio 1.26, 95% CI 1.02-1.56).
        </p>
        <p class="headingAnchor" id="H89201049">
         <span class="h2">
          Postnatal effects
         </span>
        </p>
        <p class="headingAnchor" id="H89201057">
         <span class="h3">
          Neonatal toxicity and withdrawal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic administration of antipsychotics during the third trimester may cause symptoms of neonatal toxicity and withdrawal, including [
         <a href="#rid1">
          1,5,23,34,37,38
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal movements (dyskinesia)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormally increased or decreased muscle tone
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Agitation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Crying
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperactivity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperreflexia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Irritability
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Motor restlessness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tremor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypotension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tachycardia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Difficulty breathing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Difficulty feeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal dysfunction (eg, functional bowel obstruction)
        </p>
        <p>
        </p>
        <p>
         Many of the symptoms of toxicity and withdrawal were described in a US Food and Drug Administration warning [
         <a href="#rid38">
          38
         </a>
         ]. Although the incidence of these symptoms is not known, extrapyramidal symptoms (eg, abnormal movements, restlessness, and tremor) may be more likely to occur with first-generation antipsychotics and
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         than with other second-generation antipsychotics [
         <a href="#rid3">
          3
         </a>
         ]. Symptoms typically subside within hours to days, but may persist for weeks to months after birth [
         <a href="#rid3">
          3
         </a>
         ]. Specific treatment is usually not necessary, but more severely affected newborns may require longer hospital stays [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H89201266">
         <span class="h3">
          Developmental effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intrauterine exposure to antipsychotics may adversely affect neuromotor functioning during infancy. A prospective observational study was conducted six months postpartum and controlled for maternal psychiatric status and other variables; neuromotor performance (eg, posture, muscle tone, and reflexes) was poorer in babies with prenatal antipsychotic exposure (n = 22) compared with babies with no prenatal psychotropic exposure (n = 85) [
         <a href="#rid22">
          22
         </a>
         ]. However, assessment at six months may not predict long-term outcome. In addition, information processing and learning were comparable for the two groups.
        </p>
        <p>
         However, prenatal exposure to antipsychotics does not appear to be associated with psychopathology in the offspring. A retrospective study of electronic medical records identified mother-child pairs (n &gt;400,000), including children with gestational exposure to antipsychotics (n = 706) [
         <a href="#rid39">
          39
         </a>
         ]. The analyses controlled for potential confounding factors observed at baseline, such as maternal age and general medical and psychiatric disorders, based upon the probability (propensity) of receiving treatment. The risk of attention-deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) in the exposed and nonexposed children was comparable. In addition, an analysis of sibling pairs, one exposed in utero to antipsychotics and the other not, suggested that exposure to antipsychotics did not increase the risk of ADHD or ASD.
        </p>
        <p class="headingAnchor" id="H481720">
         <span class="h2">
          First-generation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reproductive safety risks of first-generation antipsychotics are generally regarded as low, based upon a literature that extends back to the 1960s [
         <a href="#rid2">
          2,4,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10923897">
         <span class="h3">
          Perinatal mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of first-generation antipsychotics during pregnancy does not appear to increase perinatal mortality [
         <a href="#rid40">
          40
         </a>
         ]. A prospective observational study found that the frequency of stillbirths and neonatal deaths were each similar in patients treated with typical antipsychotics (n &gt;3000) and in untreated patients (n &gt;38,000) [
         <a href="#rid41">
          41
         </a>
         ]. Perinatal mortality is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4973.html" rel="external">
          "Perinatal mortality"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10923903">
         <span class="h3">
          Teratogenicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most studies have not found an increased risk of birth defects following prenatal exposure to first-generation antipsychotics, including
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">
          prochlorperazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         [
         <a href="#rid1">
          1,3,4
         </a>
         ]. Although a 1996 meta-analysis of three prospective observational studies and one retrospective study (n &gt;2500 live birth infants exposed to first-generation antipsychotics during pregnancy and n &gt;71,000 unexposed infants) found a small increased risk of congenital malformations (odds ratio 1.2) [
         <a href="#rid23">
          23
         </a>
         ], subsequent prospective studies have not [
         <a href="#rid40">
          40
         </a>
         ]. As an example, a prospective observational study found that congenital malformations were comparable in newborns exposed in utero to haloperidol or penfluridol (n = 128) and in unexposed newborns (n = 581; 3 versus 4 percent) [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10924649">
         <span class="h3">
          Preterm birth
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antenatal exposure to first-generation antipsychotics may be associated with spontaneous preterm birth. In a prospective observational study of pregnant women exposed to either first-generation antipsychotics (n = 284) or nonteratogenic drugs (n = 1122), premature delivery occurred more often in the group with first-generation antipsychotic exposure (16 versus 9 percent) [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10924655">
         <span class="h3">
          Birth weight
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although it is not clear if prenatal exposure to first-generation antipsychotics are associated with abnormal birth weight, larger studies have failed to find such an association. Two prospective observational studies found that birth weights were comparable for infants exposed to first-generation antipsychotics (n = 2860 and 229) and for unexposed infants (n = 35,353 and 1122) [
         <a href="#rid40">
          40,41
         </a>
         ]. By contrast, two smaller prospective observational studies (n = 846 and 83) each found that birth weights were less (approximately 220 grams) in babies exposed to typical antipsychotics compared with unexposed babies [
         <a href="#rid37">
          37,42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10924661">
         <span class="h3">
          Postnatal effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonatal disorders may be associated with late term, in utero exposure to first-generation antipsychotics. A prospective observational study of pregnant women who received either first-generation antipsychotics (n = 284) or nonteratogenic drugs (n = 1122) found that disorders in the newborn occurred more often in the group with first-generation antipsychotic exposure (22 versus 4 percent of newborns) [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Reviews have concluded that prenatal exposure to first-generation antipsychotics does not appear to adversely affect behavioral, cognitive, or emotional development [
         <a href="#rid2">
          2,43,44
         </a>
         ]. As an example, a prospective observational study of children exposed in utero to typical antipsychotics (n &gt;2000) and children not exposed (n &gt;26,000) found that intelligence quotient scores measured at four years of age were comparable [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1561513">
         <span class="h2">
          Second-generation
         </span>
        </p>
        <p class="headingAnchor" id="H97877957">
         <span class="h3">
          Perinatal mortality and teratogenicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Second-generation antipsychotics are usually not associated with fetal deaths (stillbirths) or teratogenic effects [
         <a href="#rid1">
          1,3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective observational study compared outcomes in 151 pregnant patients treated during the first trimester with atypical antipsychotics (primarily
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ) and a comparison group of 151 unexposed pregnant women. The rate of spontaneous abortions, stillbirths, and major congenital malformations were each comparable for the two groups [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent prospective observational study found that the rate of spontaneous abortions, stillbirths, and major congenital malformations were each comparable in 133 pregnant patients treated with atypical antipsychotics (usually throughout the entire pregnancy) and 133 unexposed pregnant women [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In addition, the reported rates of fetal death and congenital malformations for specific second-generation drugs generally do not exceed rates in the general population:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aripiprazole
         </strong>
         – A prospective observational study included 71 pregnant women who were exposed during the first trimester to
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         (usually in conjunction with antidepressants, antiepileptics, other antipsychotics and/or benzodiazepines), and 161 pregnant women who were not exposed [
         <a href="#rid46">
          46
         </a>
         ]. The incidence of major malformations was comparable for the exposed and unexposed groups (2.8 and 1.2 percent), as was the incidence of major plus minor malformations (8.5 and 4.3 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A second prospective observational study compared 163 infants exposed to
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         in the first trimester with 690 infants of mothers with psychiatric diagnoses who did not use an atypical antipsychotic during pregnancy. After adjustment for potential confounding factors, the analyses found that the rate of major malformations in the two groups was comparable [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clozapine
         </strong>
         – The manufacturer has received 523 reports about use of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         during pregnancy; congenital anomalies occurred in 4 percent and there was no pattern of defects [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Olanzapine
         </strong>
         – The manufacturer has received 610 prospective reports about use of
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         during pregnancy; the olanzapine exposure (mean dose 10 mg per day) was initially reported during pregnancy and the outcomes were prospectively ascertained following birth [
         <a href="#rid48">
          48
         </a>
         ]. Stillbirth occurred in 5 cases (0.8 percent), including one in which a normal fetus died when the mother committed suicide at month eight of the pregnancy. In addition, congenital malformations occurred in 4 percent. The rate of stillbirth and congenital anomalies were consistent with general population rates.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Quetiapine
         </strong>
         – The manufacturer has received 298 reports about prospective and retrospective use of
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         during pregnancy (most reports involved patients who took other medications); congenital anomalies occurred in 5 percent and there was no pattern of defects [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risperidone
         </strong>
         – The manufacturer has received 713 reports about use of
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         during pregnancy. Among the 68 prospectively reported pregnancies with a known outcome, organ malformations occurred in 4 percent and spontaneous abortions in 17 percent [
         <a href="#rid49">
          49
         </a>
         ]. However, one study found that risperidone was associated with a small increased risk in overall malformations. (See
         <a class="local">
          'Teratogenicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ziprasidone
         </strong>
         – The manufacturer has received 57 reports about use of
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         during pregnancy; normal outcomes occurred in 50 cases, spontaneous abortions in 5, malformation in 1, and stillbirth in 1 [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Nevertheless, some studies have found an association between first trimester exposure and major malformations. In a prospective observational study of pregnant women exposed to either second-generation antipsychotics (n = 561, primarily women with psychotic disorders) or nonteratogenic drugs (n = 1122), major congenital malformations occurred more often in the group with second-generation antipsychotic exposure (5.2 versus 2.5 percent of babies) [
         <a href="#rid40">
          40
         </a>
         ]. Specifically, cardiovascular defects (mostly atrial and ventricular septal defects) were more frequent with second-generation antipsychotic exposure than nonteratogenic drug exposure (odds ratio 3, 95% CI 1-8). In addition, elective termination of pregnancy occurred in more women taking second-generation antipsychotics. Spontaneous abortions and stillbirths were comparable for the two groups.
        </p>
        <p class="headingAnchor" id="H97877963">
         <span class="h3">
          Birth weight
         </span>
         <span class="headingEndMark">
          —
         </span>
         The association between exposure to second-generation antipsychotics during pregnancy and birth weight is not clear due to conflicting results across prospective observational studies. Two studies found that birth weight was comparable for babies who were exposed in utero to atypical antipsychotics and babies not exposed [
         <a href="#rid40">
          40,45
         </a>
         ]. In other studies, prenatal exposure to second-generation antipsychotics was associated with large for gestational age births [
         <a href="#rid42">
          42
         </a>
         ] and higher infant birth weights [
         <a href="#rid50">
          50
         </a>
         ]. Yet other studies have found that prenatal exposure was associated with low birth weight [
         <a href="#rid19">
          19,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H97877969">
         <span class="h3">
          Postnatal effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonatal disorders may be associated with late term, in utero exposure to second-generation antipsychotics. A prospective observational study of pregnant women who received either second-generation antipsychotics (n = 561) or nonteratogenic drugs (n = 1122) found that disorders in the newborn occurred more often in the group with second-generation antipsychotic exposure (16 versus 4 percent of newborns) [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         There is little information about the association between fetal exposure to second-generation antipsychotics and behavioral, cognitive, and emotional outcomes [
         <a href="#rid3">
          3,44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1561527">
         <span class="h1">
          BENZODIAZEPINES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benzodiazepines are often used during pregnancy to manage severe anxiety or agitation, and drugs with short half-lives (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ) are preferred. This approach is consistent with practice guidelines from the United Kingdom National Institute for Health and Care Excellence [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4537124">
         <span class="h2">
          Teratogenicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to conflicting results across studies, it is not known if exposure to either benzodiazepines or hypnotic benzodiazepine receptor agonists (eg,
         <a class="drug drug_general" data-topicid="10334" href="/z/d/drug information/10334.html" rel="external">
          zaleplon
         </a>
         ,
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         , or
         <a class="drug drug_general" data-topicid="10126" href="/z/d/drug information/10126.html" rel="external">
          zopiclone
         </a>
         ) during pregnancy is associated with an increased risk of congenital malformations. However, the best data, from a systematic review that included nine observational studies with more than one million subjects, suggest that benzodiazepines are not associated with an increased risk [
         <a href="#rid51">
          51
         </a>
         ]. Meta-analyses from this systematic review and results from other observational studies not included in the review all indicate that benzodiazepines are not associated with birth defects [
         <a href="#rid52">
          52-54
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The systematic review included the following meta-analyses of prospective observational studies [
         <a href="#rid51">
          51
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A meta-analysis of five studies (n &gt;3000 exposed infants and &gt;127,000 unexposed infants) found that the risk of major congenital malformations was nearly identical for the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A meta-analysis of five studies (n &gt;6000 exposed infants and &gt;1,000,000 unexposed infants) found that the risk of cardiac malformations was similar for the two groups (however, heterogeneity across studies was large).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A meta-analysis of two studies (n &gt;3000 exposed infants and &gt;893,000 unexposed infants) found that benzodiazepines were not associated with an increased risk of orofacial cleft.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A birth registry study found that the incidence of congenital malformations was comparable for infants exposed in utero to hypnotic benzodiazepine receptor agonists (n &gt;1000) and control infants (n &gt;1,000,000; 4 and 5 percent) [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of seven cohort studies (n &gt;1000 infants exposed during pregnancy to benzodiazepines and &gt;70,000 infants not exposed) found that there was no relationship between fetal exposure to benzodiazepines and major malformations [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Nevertheless, some retrospective studies suggest that benzodiazepines or hypnotic benzodiazepine receptor agonists may be associated with congenital malformations [
         <a href="#rid23">
          23,56
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of four case-control studies (166 infants with fetal exposure to benzodiazepines and 5970 control infants not exposed) found that major malformations were associated with the use of benzodiazepines during pregnancy (odds ratio 3; 95% CI 1-7); however, heterogeneity across studies was significant [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of six case-control studies (285 infants with fetal exposure to benzodiazepines and 14,686 control infants not exposed) found that exposure was associated with an elevated risk of oral cleft (odds ratio 2; 95% CI 1-3); however, heterogeneity across studies was significant [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A birth registry study found that congenital malformations were marginally increased in newborns exposed during pregnancy to benzodiazepines or hypnotic benzodiazepine receptor agonists (n &gt;1900), compared with all newborns (n &gt;873,000; odds ratio 1.2; 95% CI 1.0-1.6) [
         <a href="#rid57">
          57
         </a>
         ]. In particular, the risk of pylorostenosis was nearly three times greater than expected and alimentary tract atresia nearly four times greater.
        </p>
        <p>
        </p>
        <p>
         To the extent that benzodiazepines are associated with teratogenic effects, many authorities consider the absolute increase small [
         <a href="#rid5">
          5,18,23
         </a>
         ]. As an example, retrospective case-control studies suggest that fetal exposure to benzodiazepines may increase the risk of oral cleft from the general population base rate of 6 in 10,000 births to 11 in 10,000 births [
         <a href="#rid5">
          5
         </a>
         ]. It is also worth noting that case-control studies may be subject to recall bias [
         <a href="#rid52">
          52
         </a>
         ]. In addition, compared with pregnant patients who do not use benzodiazepines or hypnotic benzodiazepine receptor agonists, patients using these drugs may be older and more likely to smoke and use other drugs (eg, antiepileptics, which are regarded as teratogens) [
         <a href="#rid58">
          58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">
          "Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Effects of ASMs on the fetus and child'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4537211">
         <span class="h2">
          Spontaneous abortion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benzodiazepines appear to be associated with spontaneous abortion (miscarriage). A meta-analysis of three prospective observational studies included approximately 600 pregnant women treated with benzodiazepines during the first trimester and approximately 600 unexposed pregnancies, and found that benzodiazepines were associated with an increased risk of spontaneous abortion (odds ratio 2, 95% CI 1-3) [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4537239">
         <span class="h2">
          Preterm birth
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antenatal benzodiazepines may be associated with preterm birth (eg, &lt;37 weeks gestational age). A national registry study identified pregnant women with preterm deliveries (n &gt;42,000), including women treated with benzodiazepines or hypnotic benzodiazepine receptor agonists early in the pregnancy (typically first trimester; n = 161), and women treated later in the pregnancy (n = 50) [
         <a href="#rid57">
          57
         </a>
         ]. Preterm birth occurred more often with early exposure compared with no exposure (odds ratio 1.5, 95% CI 1.3-1.8); preterm delivery was also associated with later exposure (odds ratio 2.6, 95% CI 1.9-3.4).
        </p>
        <p class="headingAnchor" id="H4537136">
         <span class="h2">
          Birth weight
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon prospective observational studies, benzodiazepines do not appear to be associated with low birth weight (eg, &lt;2500 g). A meta-analysis of three prospective observational studies included pregnant women treated with benzodiazepines (n = 478) and pregnant women not treated with benzodiazepines (n = 559), and found that risk of low birth weight was nearly identical in the two groups [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         However, one retrospective study found that use of benzodiazepines during pregnancy was associated with low birth weight. A national registry study identified low birth weight infants (n &gt;27,000), including infants exposed to benzodiazepines or hypnotic benzodiazepine receptor agonists early in the pregnancy (typically first trimester; n = 103), and infants exposed later in the pregnancy (n = 28) [
         <a href="#rid57">
          57
         </a>
         ]. Low birth weight occurred more often with early exposure compared with no exposure (odds ratio 1.3, 95% CI 1.1-1.6); low birth weight was also associated with later exposure (odds ratio 1.9, 95% CI 1.3-2.8).
        </p>
        <p class="headingAnchor" id="H4537142">
         <span class="h2">
          Postnatal effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic administration of benzodiazepines proximal to delivery can cause neonatal toxicity and withdrawal, including [
         <a href="#rid2">
          2,5,52,57
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low Apgar scores
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Apnea
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypothermia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperreflexia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertonia or hypotonia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Irritability
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lethargy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restlessness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tremor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diarrhea
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor feeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vomiting
        </p>
        <p>
        </p>
        <p>
         This toxicity and withdrawal is widely reported [
         <a href="#rid4">
          4
         </a>
         ], and may occur more often in preterm infants than term infants [
         <a href="#rid59">
          59
         </a>
         ]. Symptoms may persist for up to three months [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         It is not clear if using benzodiazepines during pregnancy adversely affects neurobehavioral development, due to conflicting results among studies [
         <a href="#rid2">
          2,44
         </a>
         ]. However, in the largest prospective study, motor and cognitive functioning were comparable at age three years for children exposed in utero to benzodiazepines (n = 1870) and unexposed children (n = 48,412) [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1561534">
         <span class="h1">
          LITHIUM
         </span>
        </p>
        <p class="headingAnchor" id="H10923798">
         <span class="h2">
          Placental passage
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         appears to completely equilibrate across the placenta. An observational study of 27 infant-mother pairs found that the ratio of lithium serum concentrations in umbilical cord blood to maternal blood was 1.1, across a wide range of maternal concentrations [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H335270393">
         <span class="h2">
          Serum concentrations
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         levels may drop as pregnancy progresses, and doses may need to be increased. (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy", section on 'Refractory patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10923828">
         <span class="h2">
          Perinatal mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is not clear if prenatal exposure to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         increases perinatal mortality, due to conflicting results across prospective observational studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study found that the frequency of miscarriages and stillbirths were each similar in patients treated with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         (n = 138) and controls (n = 148) [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         However, a second study found that miscarriages occurred in more patients exposed to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         during the first trimester (n = 183) than women exposed to nonteratogenic substances (n = 748; 16 versus 6 percent) [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         General information about perinatal mortality is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4973.html" rel="external">
          "Perinatal mortality"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10923847">
         <span class="h2">
          Teratogenicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Observational studies have found that fetal
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         exposure is associated with teratogenic effects. In a meta-analysis of four prospective and retrospective studies that compared exposed infants (n = 365) and unexposed infants (n &gt;974,000), the risk of congenital malformations was twice as great in exposed infants (odds ratio 2, 95% CI 1-4) [
         <a href="#rid51">
          51
         </a>
         ]. In addition, a subsequent prospective observational study of patients who received lithium during the first trimester (n = 123) found that anomalies occurred in 6.5 percent of infants [
         <a href="#rid63">
          63
         </a>
         ]. By comparison, the rate in pregnant bipolar patients not exposed to lithium (n = 61) was 3.3 percent, and in pregnant women exposed to nonteratogenic substances (n = 711) was 2.7 percent. However, the increased absolute risk of congenital abnormalities (7 per 1000) is considered small [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2805104514">
         <span class="h3">
          Cardiac
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antenatal
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         exposure is generally thought to be associated with teratogenic effects that primarily involve the heart [
         <a href="#rid2">
          2,5
         </a>
         ]. Cardiac malformations that have been observed include Ebstein anomaly (abnormalities of the tricuspid valve and right ventricle), right ventricular outflow tract obstruction defects, coarctation of the aorta, and mitral atresia [
         <a href="#rid5">
          5,64-66
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective observational study found that cardiovascular anomalies were more common among infants exposed to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         during the first trimester (n = 123) than infants exposed to nonteratogenic substances (n = 711; 4.1 versus 0.6 percent) [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study of an administrative claims database examined cardiac defects in infants with first trimester exposure to either
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         (n = 663) or
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         (n = 1945). After adjusting for the probability (propensity) to receive lithium or lamotrigine, based upon potential confounding factors such as maternal age, general medical and psychiatric diagnoses, and use of concomitant medications, the analyses found that cardiac defects occurred in more infants exposed to lithium than lamotrigine (2.4 versus 1.4 percent) [
         <a href="#rid67">
          67
         </a>
         ]. In addition, infants exposed to lithium were compared with infants who were not exposed to either lithium or lamotrigine (n &gt;1,000,000); right ventricular outflow tract obstruction defects were more common in lithium exposed infants than controls (0.6 versus 0.2 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other analyses suggested that the association between
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         exposure and cardiac defects may perhaps be dose-dependent. Among infants who were exposed to a maternal daily dose of 600 mg or less, the risk of cardiac malformations was 1.1 (95% CI 0.5-2.6), whereas the risk with a dose of more than 900 mg was 3.2 (95% CI 1.5-7.0).
        </p>
        <p>
        </p>
        <p>
         However, other studies suggest that
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is not associated with an increased risk of cardiac malformations, including a meta-analysis of two retrospective studies that found the risk in exposed (n = 120) and unexposed (n &gt;973,000) infants was comparable [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Ebstein anomaly may be the most common fetal cardiac defect associated with prenatal
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         exposure. The estimated risk of the anomaly in the general population is 1 in 20,000 live births [
         <a href="#rid24">
          24-26
         </a>
         ]; following first-trimester exposure to lithium, the risk appears to increase 20-fold to approximately 1 in 1000 [
         <a href="#rid68">
          68
         </a>
         ], an absolute risk that many authorities consider low [
         <a href="#rid2">
          2,5,23,27,69
         </a>
         ]. However, the evidence that lithium causes the anomaly is uncertain [
         <a href="#rid35">
          35
         </a>
         ]. As an example, a meta-analysis of six observational studies (n = 264) found that antenatal exposure to lithium did not differ statistically between cases of Ebstein anomaly and controls without the defect [
         <a href="#rid70">
          70
         </a>
         ]. While the odds ratio estimate was not statistically significant, the upper confidence level was consistent with an increased risk of the malformation, suggesting that there is uncertainty about the risk of harm. In addition, a retrospective study of an administrative claims database, which identified infants with first trimester exposure to lithium (n = 663), found that none of the infants were diagnosed with Ebstein anomaly [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         Ebstein anomaly is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8146.html" rel="external">
          "Ebstein anomaly: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10923934">
         <span class="h2">
          Preterm birth
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         during pregnancy may be associated with preterm delivery. A prospective observational study found that preterm birth occurred in more patients treated with lithium during the first trimester (n = 131) than patients treated with nonteratogenic substances (n = 683; 14 versus 6 percent) [
         <a href="#rid63">
          63
         </a>
         ]. An overview of preterm delivery is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6798.html" rel="external">
          "Preterm labor: Clinical findings, diagnostic evaluation, and initial treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10923966">
         <span class="h2">
          Birth weight
         </span>
         <span class="headingEndMark">
          —
         </span>
         Birth weight may be increased in babies exposed in utero to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , but the increase does not appear to be clinically significant. A prospective observational study found that birth weight was greater in lithium exposed babies (n = 138) than unexposed babies (n = 148; 3475 versus 3383 grams) [
         <a href="#rid62">
          62
         </a>
         ]. Maternal lithium dose was not correlated with birth weight.
        </p>
        <p class="headingAnchor" id="H10924543">
         <span class="h2">
          Postnatal effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         during the second and third trimester can result in neonatal complications, including [
         <a href="#rid4">
          4,6,7,34,71-73
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiomegaly
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Goiter and hypothyroidism
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatomegaly
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arginine vasopressin resistance (previously called nephrogenic diabetes insipidus)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polyhydramnios
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Premature labor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shock
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         toxicity can also occur in newborns with late pregnancy exposure; symptoms include [
         <a href="#rid4">
          4,6,7,34,71-73
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low Apgar scores
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Apnea, shallow respirations, and cyanosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bradycardia or tachycardia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac arrhythmias and abnormal electrocardiogram
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Feeding difficulties
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lethargy or coma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Muscle flaccidity and hypotonia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor suck, grasp, and Moro reflexes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seizures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Twitching
        </p>
        <p>
        </p>
        <p>
         Neonatal
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         toxicity and complications are more common in newborns with higher serum lithium concentrations. In a study of 24 infants exposed in utero to lithium, lower Apgar scores, higher rates of central nervous system and neuromuscular complications, and longer hospital stays were observed in infants born with umbilical cord serum lithium concentrations &gt;0.6 mEq/L (0.6 mmol/L), compared with infants with lower concentrations [
         <a href="#rid61">
          61
         </a>
         ]. Lithium toxicity generally resolves in one to two weeks.
        </p>
        <p>
         Available studies suggest that prenatal
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         exposure does not adversely affect developmental outcomes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study found that major developmental milestones (eg, smiling, lifting head, sitting, crawling, standing, talking, and walking) were achieved at comparable ages for lithium-exposed children (n = 22) and unexposed controls (n = 148) [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study found that behavioral measures of development were comparable for children exposed to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         prenatally (n = 60) compared with their unexposed siblings (n = 57) [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another retrospective study found that intelligence quotient was comparable in children exposed to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         prenatally (n = 20), compared with unexposed children (n = 19) [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1561541">
         <span class="h1">
          ELECTROCONVULSIVE THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neither the number nor pattern of congenital malformations in children exposed in utero to electroconvulsive therapy (ECT) implicates it as a causal factor in organ dysgenesis [
         <a href="#rid5">
          5,76
         </a>
         ]. A review of 300 case reports of ECT during pregnancy found five reports of congenital anomalies, including hypertelorism, talipes equinovarus (clubfoot), optic atrophy, anencephaly, and pulmonary cysts [
         <a href="#rid77">
          77
         </a>
         ]. The review concluded that these malformations were not the result of ECT, and that there was no evidence of postnatal developmental effects. In addition, there is little or no evidence that fetal exposure to ECT adversely affects intrauterine growth, or causes neonatal toxicity or adverse developmental effects [
         <a href="#rid5">
          5
         </a>
         ]. The most common adverse effects of ECT in the mother are premature contractions and labor, and in the fetus bradyarrhythmias [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         The risk of teratogenic effects and neonatal toxicity posed by ECT anesthetic drugs appears to be low [
         <a href="#rid71">
          71,77-79
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glycopyrrolate
         </strong>
         – The anticholinergic
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         does not readily cross the placenta, and there do not appear to be any reports of teratogenesis with the injected solution.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Methohexital
         </strong>
         <strong>
          or
         </strong>
         <strong>
          propofol
         </strong>
         – Although the general anesthetics
         <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">
          methohexital
         </a>
         and
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         cross the placenta, there do not appear to be any reports of teratogenesis with either drug.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Succinylcholine
         </strong>
         – The muscle relaxant
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         generally does not appear to significantly affect the fetus; typically, only a small amount at most crosses the placenta.
        </p>
        <p>
        </p>
        <p>
         In addition, it is unlikely that these drugs cause congenital malformations and toxicity because of the infrequent and brief exposure that occurs during a course of ECT.
        </p>
        <p class="headingAnchor" id="H2864397663">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115361.html" rel="external">
          "Society guideline links: Bipolar disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H87632536">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition of a teratogen
         </strong>
         – Teratogens are factors that can alter normal intrauterine development of fetal growth, anatomic structures, physical functioning, and postnatal development. This definition encompasses environmental exposures (eg, drugs), maternal medical disorders, infectious agents, and genetic conditions. (See
         <a class="local">
          'Definition of a teratogen'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/110900.html" rel="external">
          "Congenital anomalies: Causes", section on 'Teratogens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychotropic drugs and teratogenicity
         </strong>
         – The estimated risk of major congenital malformations appears to vary among psychotropic medications; the rank order from greatest to least teratogenic risk is (see
         <a class="local">
          'General principles'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          Valproate
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          Carbamazepine
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          Lamotrigine
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antipsychotics
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antidepressants
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Quality of evidence
         </strong>
         – Much of the evidence about the teratogenicity, pregnancy complications, and postnatal risks associated with antidepressants is based upon observational studies of pregnant patients with unipolar major depression.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/89067.html" rel="external">
          "Antenatal use of antidepressants and the potential risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/100334.html" rel="external">
          "Antenatal use of antidepressants and risks of teratogenicity and adverse pregnancy outcomes: Drugs other than selective serotonin reuptake inhibitors"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5007.html" rel="external">
          "Antenatal exposure to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs): Neonatal outcomes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiparkinsonian drugs
         </strong>
         – Among the antiparkinsonian drugs that are used to treat extrapyramidal symptoms secondary to antipsychotics, reviews suggest that organ malformation appears to be less likely with
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         than
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">
          benztropine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         . (See
         <a class="local">
          'Antiparkinsonian drugs used for treating extrapyramidal symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiepileptics
         </strong>
         – Most observational studies that have examined the association between antiepileptics and congenital malformations and postnatal risks have been conducted primarily in pregnant patients with epilepsy. (See
         <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">
          "Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Effects of ASMs on the fetus and child'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antipsychotics
         </strong>
         – Most studies have found that exposure during pregnancy to first- and second-generation antipsychotics does not appear to increase the risk of major physical malformations above rates observed in the general population. However, chronic administration of antipsychotics during the third trimester may cause symptoms of neonatal toxicity and withdrawal. (See
         <a class="local">
          'Antipsychotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benzodiazepines
         </strong>
         – The best evidence suggests that exposure to benzodiazepines or to hypnotic, benzodiazepine receptor agonists during pregnancy is not associated with an increased risk of congenital malformations. Benzodiazepines also do not appear to be associated with low birth weight. However, antenatal exposure to benzodiazepines appears to be associated with spontaneous abortion and preterm birth. Chronic administration of benzodiazepines proximal to delivery can cause neonatal toxicity and withdrawal. (See
         <a class="local">
          'Benzodiazepines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lithium
         </strong>
         – Although observational studies have found that fetal
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         exposure is associated with teratogenic effects, the increased absolute risk of congenital abnormalities (7 per 1000) is considered small. The associated teratogenic effects may involve the heart (eg, Ebstein anomaly of the tricuspid valve), but the results from different studies are conflicting as to whether antenatal lithium exposure is associated with cardiac defects. Second and third trimester lithium exposure can lead to neonatal complications and lithium toxicity. (See
         <a class="local">
          'Lithium'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electroconvulsive therapy
         </strong>
         – Neither the number nor pattern of congenital malformations in children exposed in utero to electroconvulsive therapy (ECT) implicates it as a causal factor in organ dysgenesis. The risk of neonatal toxicity and adverse developmental effects posed by ECT also appears to be low. (See
         <a class="local">
          'Electroconvulsive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Owen JA. Psychopharmacology. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL (Ed), American Psychiatric Publishing, Inc., Washington, DC 2011. p.957.
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001. Reaffirmed Obstet Gynecol 2018; 131:185. Reaffirmed 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009; 15:183.
          </a>
         </li>
         <li class="breakAll">
          Newport DJ, Fernandez SV, Juric S, Stowe ZN. Psychopharmacology during pregnancy and lactation. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.1373.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.
          </a>
         </li>
         <li class="breakAll">
          Frey BN, Macritchie KA, Soares CN, Steiner M. Bipolar disorder in women. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex 2010. p.463.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menon SJ. Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet 2008; 277:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009; 27:993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunnington M, Ferber S, Quartey G, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 2007; 48:1207.
          </a>
         </li>
         <li class="breakAll">
          Stewart DE, Vigod SN, Stotland NL. Obstetrics and gynecology. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL (Ed), American Psychiatric Publishing, Inc, Washington, DC 2011. p.797.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.
          </a>
         </li>
         <li class="breakAll">
          Post RM, Altshuler LL. Mood disorders: Treatment of bipolar disorders. In: Kaplan &amp; Sadock's Comprehensive Textbook of Psychiatry, 9th edition, Sadock BJ, Sadock VA, Ruiz P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Vol I, p.1743.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viguera AC, Koukopoulos A, Muzina DJ, Baldessarini RJ. Teratogenicity and anticonvulsants: lessons from neurology to psychiatry. J Clin Psychiatry 2007; 68 Suppl 9:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psychiatr Pract 2005; 11:177.
          </a>
         </li>
         <li class="breakAll">
          CDC. Update on Overall Prevalence of Major Birth Defects --- Atlanta, Georgia, 1978--2005 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5701a2.htm (Accessed on May 24, 2011).
         </li>
         <li class="breakAll">
          New York State Department of Health (2010). Congenital Malformations Registry Summary Report, Statistical Summary of Children Born in 2006 and Diagnosed Through 2008. http://www.health.ny.gov/ (Accessed on December 26, 2011).
         </li>
         <li class="breakAll">
          Swedish National Board of Health and Welfare, Center for Epidemiology (2004). Registration of Congenital Malformations in the Swedish Health Registers, 1995-2001. http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/10350/2004-112-1_20041121.pdf (Accessed on December 26, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dolovich LR, Addis A, Vaillancourt JM, et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998; 317:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005; 66:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burt VK, Bernstein C, Rosenstein WS, Altshuler LL. Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications. Am J Psychiatry 2010; 167:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007; 164:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson KC, LaPrairie JL, Brennan PA, et al. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry 2012; 69:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lupo PJ, Langlois PH, Mitchell LE. Epidemiology of Ebstein anomaly: prevalence and patterns in Texas, 1999-2005. Am J Med Genet A 2011; 155A:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa-Villaseñor A, Ferencz C, Neill CA, et al. Ebstein's malformation of the tricuspid valve: genetic and environmental factors. The Baltimore-Washington Infant Study Group. Teratology 1994; 50:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pradat P, Francannet C, Harris JA, Robert E. The epidemiology of cardiovascular defects, part I: a study based on data from three large registries of congenital malformations. Pediatr Cardiol 2003; 24:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen LS, Wang B, Nonacs R, et al. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am 2010; 33:273.
          </a>
         </li>
         <li class="breakAll">
          Briggs GG, Freeman RK, Yaffe SJ. Diphenhydramine. In: Drugs in Pregnancy and Lactation, 9th edition, Lippincott Williams &amp; Wilkins, Philadelphia 2009. p.844.
         </li>
         <li class="breakAll">
          Burt VK, Stein K. Treatment of women. In: The American Psychiatric Publishing Textbook of Psychiatry, Fifth Edition, Hales RE, Yodofsky SC, Gabbard GO (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.1489.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aselton P, Jick H, Milunsky A, et al. First-trimester drug use and congenital disorders. Obstet Gynecol 1985; 65:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxén I. Letter: Cleft palate and maternal diphenhydramine intake. Lancet 1974; 1:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008; 28:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toh S, Li Q, Cheetham TC, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries. Arch Womens Ment Health 2013; 16:149.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38, 2006. http://www.nice.org.uk/ (Accessed on March 07, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones I, Chandra PS, Dazzan P, Howard LM. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet 2014; 384:1789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry 2016; 73:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diav-Citrin O, Shechtman S, Ornoy S, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005; 66:317.
          </a>
         </li>
         <li class="breakAll">
          FDA Drug SafetyCommunication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm (Accessed on March 01, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Z, Chan AYL, Coghill D, et al. Association Between Prenatal Exposure to Antipsychotics and Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Preterm Birth, and Small for Gestational Age. JAMA Intern Med 2021; 181:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habermann F, Fritzsche J, Fuhlbrück F, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol 2013; 33:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slone D, Siskind V, Heinonen OP, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977; 128:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newham JJ, Thomas SH, MacRitchie K, et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 2008; 192:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yaeger D, Smith HG, Altshuler LL. Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum. Am J Psychiatry 2006; 163:2064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gentile S. Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depress Anxiety 2010; 27:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadowski A, Todorow M, Yazdani Brojeni P, et al. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open 2013; 3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellet F, Beyens MN, Bernard N, et al. Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study. Pharmacoepidemiol Drug Saf 2015; 24:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman MP, Viguera AC, Góez-Mogollón L, et al. Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Arch Womens Ment Health 2021; 24:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunner E, Falk DM, Jones M, et al. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol 2013; 14:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coppola D, Russo LJ, Kwarta RF Jr, et al. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 2007; 30:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babu GN, Desai G, Tippeswamy H, Chandra PS. Birth weight and use of olanzapine in pregnancy: a prospective comparative study. J Clin Psychopharmacol 2010; 30:331.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence (NICE). Antenatal and postnatal mental health: clinical management and service guidance. NICE clinical guideline 192. December 2014. http://www.nice.org.uk/guidance/cg192 (Accessed on August 27, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eros E, Czeizel AE, Rockenbauer M, et al. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2002; 101:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reis M, Källén B. Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open 2013; 3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wikner BN, Källén B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans? J Clin Psychopharmacol 2011; 31:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002; 53:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wikner BN, Stiller CO, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wikner BN, Stiller CO, Källén B, Asker C. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol Drug Saf 2007; 16:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. Br Med J (Clin Res Ed) 1981; 282:1106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartz SC, Heinonen OP, Shapiro S, et al. Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. N Engl J Med 1975; 292:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newport DJ, Viguera AC, Beach AJ, et al. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry 2005; 162:2162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobson SJ, Jones K, Johnson K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992; 339:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diav-Citrin O, Shechtman S, Tahover E, et al. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry 2014; 171:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein MR, Goldfield M. Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 1975; 132:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen HT, Sharma V, McIntyre RS. Teratogenesis associated with antibipolar agents. Adv Ther 2009; 26:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patorno E, Huybrechts KF, Bateman BT, et al. Lithium Use in Pregnancy and the Risk of Cardiac Malformations. N Engl J Med 2017; 376:2245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen LS. Treatment of bipolar disorder during pregnancy. J Clin Psychiatry 2007; 68 Suppl 9:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011; 24:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379:721.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Use of electroconvulsive therapy in special populations. In: The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, Second Edition, American Psychiatric Association, Washington, DC 2001. p.31.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iqbal MM, Gundlapalli SP, Ryan WG, et al. Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants. South Med J 2001; 94:304.
          </a>
         </li>
         <li class="breakAll">
          Briggs GG, Freeman RK, Yaffe SJ. Lithium. In: Drugs in Pregnancy and Lactation, 9th edition, Lippincott Williams &amp; Wilkins, Philadelphia 2009. p.844.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schou M. What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 1976; 54:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forsberg L, Adler M, Römer Ek I, et al. Maternal mood disorders and lithium exposure in utero were not associated with poor cognitive development during childhood. Acta Paediatr 2018; 107:1379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bulut M, Bez Y, Kaya MC, et al. Electroconvulsive therapy for mood disorders in pregnancy. J ECT 2013; 29:e19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994; 45:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med 2009; 71:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabheru K. The use of electroconvulsive therapy in special patient populations. Can J Psychiatry 2001; 46:710.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 17159 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Owen JA. Psychopharmacology. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL (Ed), American Psychiatric Publishing, Inc., Washington, DC 2011. p.957.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378767" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19461391" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Use and safety of antipsychotic drugs during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19461391" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Use and safety of antipsychotic drugs during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15056503" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Management of bipolar disorder during pregnancy and the postpartum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15056503" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Management of bipolar disorder during pregnancy and the postpartum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17710428" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Psychotropic medication during pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19853219" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Teratogenic effects of antiepileptic medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17381445" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17381445" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19329543" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19329543" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17764382" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Teratogenicity and anticonvulsants: lessons from neurology to psychiatry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920391" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Psychotropic drugs in pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920391" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Psychotropic drugs in pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920391" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Psychotropic drugs in pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920391" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Psychotropic drugs in pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9748174" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15816786" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20693466" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17671284" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22474072" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prenatal antipsychotic exposure and neuromotor performance during infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8615404" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21465650" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Epidemiology of Ebstein anomaly: prevalence and patterns in Texas, 1999-2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7801301" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Ebstein's malformation of the tricuspid valve: genetic and environmental factors. The Baltimore-Washington Infant Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12632215" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The epidemiology of cardiovascular defects, part I: a study based on data from three large registries of congenital malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385337" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Treatment of mood disorders during pregnancy and postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385337" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Treatment of mood disorders during pregnancy and postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385337" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Treatment of mood disorders during pregnancy and postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3982720" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : First-trimester drug use and congenital disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4131054" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Letter: Cleft palate and maternal diphenhydramine intake.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18480684" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Maternal use of antipsychotics in early pregnancy and delivery outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23389622" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23389622" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25455249" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27540849" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15766297" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15766297" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34398171" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Association Between Prenatal Exposure to Antipsychotics and Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Preterm Birth, and Small for Gestational Age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23764684" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/879206" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18450655" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17151155" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20583298" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Neurodevelopmental effects of prenatal exposure to psychotropic medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23852139" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25683615" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33710399" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23902726" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17343431" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20473073" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Birth weight and use of olanzapine in pregnancy: a prospective comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20473073" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Birth weight and use of olanzapine in pregnancy: a prospective comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9545362" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Drugs in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11858890" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23427202" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21508851" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Are hypnotic benzodiazepine receptor agonists teratogenic in humans?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11773648" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17894421" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17323407" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6113019" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Effect of maternal lorazepam on the neonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1113782" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16263858" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1346886" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24781368" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1119612" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cardiovascular malformations with lithium use during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19330496" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Teratogenesis associated with antibipolar agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8031346" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A reevaluation of risk of in utero exposure to lithium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28591541" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Lithium Use in Pregnancy and the Risk of Cardiac Malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17764378" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Treatment of bipolar disorder during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21088587" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Drug treatment for mood disorders in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22265699" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Lithium toxicity profile: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22265699" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Lithium toxicity profile: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11284518" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11284518" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/970196" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : What happened later to the lithium babies? A follow-up study of children born without malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29150869" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Maternal mood disorders and lithium exposure in utero were not associated with poor cognitive development during childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23519218" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Electroconvulsive therapy for mood disorders in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8045538" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Use of electroconvulsive therapy during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19073751" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : ECT in pregnancy: a review of the literature from 1941 to 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11692973" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The use of electroconvulsive therapy in special patient populations.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
